Skip to main content
2023 Midyear Clinical Meeting & Exhibition Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Certfified Pharmacy Executive Leader (CPEL)
Certfified Pharmacy Executive Leader (CPEL)
Integrated Informatics Institute
Integrated Informatics Institute
Back
Handout

Clinical Sessions for Recertification

Educational Sessions

Board Certification Activities

Emerging Therapies and Clinical Controversies in the Management of Diffuse Large B-Cell Lymphoma

Tuesday, December 5, 2023
8:00 AM – 10:00 AM  
Location: ACC North, Room 256, 200 Level
CE Credits 2.00 contact hours
Planned in cooperation with the American College of Clinical Pharmacy
Activity #: 0217-9999-23-075-L01-P
Activity Type: Application-based
Target Audience: Pharmacist, Board-Certified Pharmacist
NOTE: This session is part of the Live Intensive Studies and Clinical Sessions packages. All attendees may attend these thought-provoking and highly educational sessions. However, if you are board certified, you must purchase the package(s) for your specialty to receive the recertification assessment and claim the recertification credit.

In this session, up-to-date literature on DLBCL treatment will be presented by subject matter experts in this field. There will be interactive patient cases that will be used to highlight how to best integrate new therapies and considerations regarding the identified therapeutic controversies that exist in DLBCL. In-depth discussion on recent literature and clinical pearls on managing the safety and administration of newer therapies will also be provided.

This activity is approved for Board Certified Oncology Pharmacist (BCOP) recertification credit.

Learning Objectives:

  • Assess clinical data evaluating the integration of new therapies into the first-line treatment of diffuse large B-cell lymphoma (DLBCL).
  • Compare central nervous system prophylaxis strategies for high-risk patients with DLBCL.
  • Identify considerations for sequencing new therapeutic modalities for relapsed/refractory DLBCL.
  • Apply recently published literature evaluating the role of chimeric antigen receptor T-cell therapies in DLBCL.
  • Recommend supportive care measures for managing unique toxicities associated with newer therapies for DLBCL.